GlassScriptPhysician profile
Douglas D Harkins
NPI 1457376915
$14,018.87
in general payments reported to CMS, 2019-2025
39 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,754 · 2020: $1,276 · 2021: $2,559 · 2022: $2,713 · 2023: $1,575 · 2024: $1,559 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,114.66 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $1,902.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,249.95 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,223.75 | 2019-2025 | Jardiance |
| Medtronic, INC. | $1,176.99 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $832.20 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $799.48 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $625.89 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $572.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $516.76 | 2021-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $350.42 | 2021-2025 | Ambulatory Monitoring & Diagnostics Undivided, Lm Undivided |
| Esperion Therapeutics, INC. | $297.46 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $258.13 | 2019-2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.55 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $161.34 | 2023-2025 | Ozempic, Wegovy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Harkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.